Age, Biography and Wiki
Stefan D. Anker was born on 1965 in Berlin, Germany, is a German cardiologist. Discover Stefan D. Anker's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 59 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
59 years old |
| Zodiac Sign |
N/A |
| Born |
1965 |
| Birthday |
|
| Birthplace |
Berlin, Germany |
| Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous with the age 59 years old group.
Stefan D. Anker Height, Weight & Measurements
At 59 years old, Stefan D. Anker height not available right now. We will update Stefan D. Anker's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Stefan D. Anker Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Stefan D. Anker worth at the age of 59 years old? Stefan D. Anker’s income source is mostly from being a successful . He is from . We have estimated Stefan D. Anker's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Stefan D. Anker Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.
He studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993) and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998.
Since then, he has had teaching appointments in several countries (UK, Germany, Australia, Italy).
His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy in CHF, ageing, sarcopenia and cancer.
Anker is a member of and serves on the Boards of several academic organisations.
He serves on the editorial boards of five scientific journals (including European Heart Journal and European Journal of Heart Failure ).
He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle and of ESC Heart Failure, which is the first open access heart failure journal.
Anker has been a member of the German Cardiac Society and of the European Society of Cardiology (ESC) since 1995.
In addition, he has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006.
He is currently vice president of the ESC in charge of National Cardiac Societies and Communications. He has been serving on the board of the ESC since 2012.
He was HFA President between 2012 and 2014 and he currently chairs the HFA committee on regulatory affairs.
Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).
Anker has authored more than 700 original papers, reviews, and editorials.
Total citations exceed 46,000, including over 50 papers with more than 200 citations.
He has an h-index of 104.
Main topics are heart failure, chronic disease, cachexia and biological markers.
Anker has participated in and chaired several consensus meeting and guidelines committees:
Stefan Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF, TIM-HF, BACH, AUGMENT-HF, ACT-ONE, RESHAPE-HF2, IMPULSE-HF, FAIR-HF2, Fair-HFpEF, EMPORER-HFpEF trials ).
He served in several data and safety monitoring boards (chairing five) and end-point committees (chairing three).
In 2015 and again in 2016, he was named in the Thomson Reuters Highly Cited Researchers list.
Anker has won several prizes (including two American Heart Association Young Investigator Awards ), and has obtained a number of fellowships and grants, including two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial ), two grants from the EU's Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant.
